361 related articles for article (PubMed ID: 15816500)
61. Vitamin D analogues for secondary hyperparathyroidism.
Brown AJ; Dusso AS; Slatopolsky E
Nephrol Dial Transplant; 2002; 17 Suppl 10():10-9. PubMed ID: 12386264
[TBL] [Abstract][Full Text] [Related]
62. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3).
Jones G
Semin Dial; 2007; 20(4):316-24. PubMed ID: 17635821
[TBL] [Abstract][Full Text] [Related]
63. [Frontiers in vitamin D; basic research and clinical application. Vitamin D and secondary hyperparathyroidism].
Tanaka H; Komaba H; Fukagawa M
Clin Calcium; 2011 Nov; 21(11):27-34. PubMed ID: 22040818
[TBL] [Abstract][Full Text] [Related]
64. [Paricalcitol - a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease].
Matuszkiewicz-Rowińska J; Żebrowski P
Wiad Lek; 2016; 69(5):756-759. PubMed ID: 28033603
[TBL] [Abstract][Full Text] [Related]
65. [Vitamin D, cardiovascular disease and mortality in patients with kidney disease].
Hansen D; Brandi L; Rasmussen K
Ugeskr Laeger; 2009 Dec; 171(50):3684-9. PubMed ID: 20003863
[TBL] [Abstract][Full Text] [Related]
66. Vitamin D receptor activation and prevention of arterial ageing.
Cozzolino M; Stucchi A; Rizzo MA; Soldati L; Cusi D; Ciceri P; Brenna I; Elli F; Gallieni M
Nutr Metab Cardiovasc Dis; 2012 Jul; 22(7):547-52. PubMed ID: 22633189
[TBL] [Abstract][Full Text] [Related]
67. Vitamin D metabolites and/or analogs: which D for which patient?
Mazzaferro S; Goldsmith D; Larsson TE; Massy ZA; Cozzolino M
Curr Vasc Pharmacol; 2014 Mar; 12(2):339-49. PubMed ID: 23713876
[TBL] [Abstract][Full Text] [Related]
68. [Vitamin D and survival of hemodialysis patients].
Shoji T; Nishizawa Y
Clin Calcium; 2004 Sep; 14(9):64-8. PubMed ID: 15577113
[TBL] [Abstract][Full Text] [Related]
69. Use of vitamin D analogs in chronic renal failure.
Kim G; Sprague SM
Adv Ren Replace Ther; 2002 Jul; 9(3):175-83. PubMed ID: 12203199
[TBL] [Abstract][Full Text] [Related]
70. Clinical uses of 1-alpha-hydroxy-ergocalciferol.
Park J; Rhee CM; Lau WL; Kalantar-Zadeh K
Curr Vasc Pharmacol; 2014 Mar; 12(2):306-12. PubMed ID: 23713877
[TBL] [Abstract][Full Text] [Related]
71. Paricalcitol in secondary hyperparathyroidism and the survival benefit in patients with chronic kidney disease.
Al-Baaj F; Yadav P; Al-Rifai A
J Ren Care; 2011 Jun; 37(2):75-9. PubMed ID: 21561542
[TBL] [Abstract][Full Text] [Related]
72. A new role for vitamin D receptor activation in chronic kidney disease.
Valdivielso JM; Cannata-Andía J; Coll B; Fernández E
Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1502-9. PubMed ID: 19625376
[TBL] [Abstract][Full Text] [Related]
73. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?
Wetmore JB; Quarles LD
Nat Clin Pract Nephrol; 2009 Jan; 5(1):24-33. PubMed ID: 18957950
[TBL] [Abstract][Full Text] [Related]
74. Vitamin D receptor activation and survival in chronic kidney disease.
Kovesdy CP; Kalantar-Zadeh K
Kidney Int; 2008 Jun; 73(12):1355-63. PubMed ID: 18288097
[TBL] [Abstract][Full Text] [Related]
75. Vitamin D analogs: perspectives for treatment.
Brown AJ; Slatopolsky E
Miner Electrolyte Metab; 1999; 25(4-6):337-41. PubMed ID: 10681662
[TBL] [Abstract][Full Text] [Related]
76. Shining D' light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D.
Petchey WG; Johnson DW; Isbel NM
Nephrology (Carlton); 2011 May; 16(4):351-67. PubMed ID: 21323790
[TBL] [Abstract][Full Text] [Related]
77. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease.
Wu-Wong JR
Br J Pharmacol; 2009 Sep; 158(2):395-412. PubMed ID: 19371337
[TBL] [Abstract][Full Text] [Related]
78. Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both?
Cannella G; Messa P
J Nephrol; 2006; 19(4):399-402. PubMed ID: 17048195
[TBL] [Abstract][Full Text] [Related]
79. Vitamin D and vitamin D receptor activators in treatment of hypertension and cardiovascular disease.
Franczyk A; Stolarz-Skrzypek K; Wesołowska A; Czarnecka D
Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):34-44. PubMed ID: 24597598
[TBL] [Abstract][Full Text] [Related]
80. Treatment Failure of Active Vitamin D Therapy in Chronic Kidney Disease: Predictive Factors.
Cozzolino M; Covic A; Martinez-Placencia B; Xynos K
Am J Nephrol; 2015; 42(3):228-36. PubMed ID: 26439891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
